Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who’s really a good candidate to toss their specs? “It’s not bringing anybody back to being 20 again,” cautioned Dr. Shilpa Rose, a Washington ophthalmologist who tests whether patients’ eyes are healthy enough to qualify.
Category: Ophthalmology
AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 03, 2017 — Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017 at 8:30am PT in Dana Point, Calif. AGTC’s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
New help for blurry close-up vision
Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who’s really a good candidate to toss their specs? “It’s not bringing anybody back to being 20 again,” cautioned Dr. Shilpa Rose, a Washington ophthalmologist who tests whether patients’ eyes are healthy enough to qualify.
Those with blurry close-up vision get some new help
Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who’s really a good candidate to toss their specs? “It’s not bringing anybody back to being 20 again,” cautioned Dr. Shilpa Rose, a Washington ophthalmologist who tests whether patients’ eyes are healthy enough to qualify.
Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments
Santen, Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., the specialty ophthalmology company headquartered in Osaka, Japan, and twoXAR, Inc., an artificial intelligence-driven biopharmaceutical company, today announced that the two companies have entered into a strategic research collaboration focused on the identification of new drug candidates for glaucoma. Under the agreement, twoXAR will use its proprietary computational drug discovery platform to discover, screen, and prioritize novel drug candidates with potential application in ocular indications, with a specific focus on glaucoma.
Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D.,…
Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety, reporting to Kristine Erickson, O.D., Ph.D., Aerie’s Vice President Clinical Research. Dr. Sheng will be responsible for the development and implementation of Aerie’s drug safety surveillance and clinical research strategy, and the management and oversight of Aerie’s clinical development and drug safety programs.
The way forward
Royal College of Opthamologists – These reports were commissioned by RCOpth to identify current methods of working and schemes devised by ophthalmology departments in the UK to help meet the increasing demand in ophthalmic services. The work found that increasing demand for hospital eye services is not being met and continues to grow – currently seeing nearly ten per cent of all outpatient appointments and performing six per cent of the surgery in the UK.
Highland Ophthalmology Associates Offering New FDA-Approved Avedro…
… finest ophthalmologists and optometrists, making Hudson Valley a destination for people who want the best in eye health and vision correction. The medical team of experienced, highly respected and devoted specialists is comprised of Dr. Mary …
Puerto Rico Ophthalmologist Group Settles FTC Charges that Members…
The complaint charges that OFTACOOP – also known as Cooperativa de MA dico OftalmA3logos de Puerto Rico – unlawfully orchestrated an agreement among competing ophthalmologists to refuse to deal with a health plan, MCS Advantage, Inc., and its network administrator, Eye Management of Puerto Rico, LLC. OFTACOOP’s concerted refusal to deal forced MCS to abandon its plan to engage Eye Management to create a lower-cost network of ophthalmologists. MCS was also forced to maintain its then-current reimbursement rates paid to ophthalmologists.
Experimental Drug Shows Promise for Sight-Stealing Eye Condition
… and a leading cause of vision loss among people age 60 and older, according to the U.S. National Institutes of Health. The condition causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp …
Ophthalmic Diagnostic Equipment Market Poised for Steady Growth in the Future
… more number of people are opting for ophthalmic surgeries to rectify their eye-related disorders. As per the World Health Organization (WHO) 2010 estimates, there were 285 Mn visually impaired people across the globe in 2010, which included 39 Mn …
English
… f the highest-quality eye care. Our EyeSmartA program provides the public with the most trusted information about eye health. For more information, visit aao.org .